评估 AMG 510 口服每日一次用于带有 KRAS p.G12C 突变的晚期／转移性实体瘤的中国裔受试者的安全性、耐受性、药物动力学及初步疗效。
适应症：Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation
入组条件
纳入标准
- Male or female subjects greater than or equal to 18 years old
- Subject is of Chinese ancestry
- Pathologically documented, advanced/metastatic solid tumor with KRAS p.G12C mutation identified
排除标准
- Active brain metastases from non-brain tumors.
- Myocardial infarction within 6 months of study day 1.
- Gastrointestinal (GI) tract disease causing the inability to take oral medication
入组条件维持 ClinicalTrials.gov 原始英文登记资料，实际入组资格以研究团队的正式评估与受试者知情同意书为准。资料来源：ClinicalTrials.gov，每两周自动更新，最后同步：2026年10月8日。